Stockwatch: Biotech Triggers Its Own Sell-Off
This article was originally published in Scrip
Last week, second-quarter earnings season degenerated not just into the long tail of loss-making companies reporting, well, their losses, but into a savage sell-off that even took the shine off the good news. Stock market commentators will look to various factors to explain the sell-off, but this time there is no single underlying cause. It was triggered by a set of independent, unconnected and cumulative events.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.